B37.3
Conditions
Interventions
Group 1: In the study, the intervention consists of an additional, one-off vaginal swab taken from adult women diagnosed with vulvovaginal candidiasis. This is a one-off procedure for each patient, ta
Sponsors
Dr. Pfleger Arzneimittel GmbH
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Women aged 18 years and over • Acute and/or chronic recurrent vulvovaginal candidiasis • Confirmed diagnosis of vulvovaginal candidiasis in accordance with the guideline (AWMF 015/072) (medical history, clinical presentation, unstained smear)
Exclusion criteria
Exclusion criteria: • Females under 18 years of age • Other gynaecological infections other than vulvovaginal candidiasis (e.g. bacterial vaginosis, trichomoniasis or similar) • Current treatment with antifungal or antibiotic medication for infections of the external and/or internal genital area
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In vitro activity of nystatin against various Candida strains. Susceptibility testing following the culture of Candida species in the central laboratory. Vaginal swab following diagnosis of vulvovaginal candidiasis by the treating gynaecologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| In vitro activity of other clinically relevant antifungal agents against the isolated Candida strains | — |
Countries
Germany
Contacts
Public ContactWerner Mendling
Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe an der Landesfrauenklinik Helios Universitätsklinikum Wuppertal
Outcome results
None listed